This retrospective study measured direct cost of care and patient out-of-pocket (OOP) spending for Medicare Fee-For-Service (FFS) beneficiaries with advanced melanoma (advMelanoma), advanced renal cell carcinoma (aRCC), or advanced non-small cell lung cancer (aNSCLC).